Efficacy and safety of cholesterol absorption inhibitors combined with statins in the treatment of dyslipidemia：a network meta-analysis
- VernacularTitle:胆固醇吸收抑制剂联合他汀类药物治疗血脂异常有效性和安全性的网状Meta分析
- Author:
Gerile HUANG
1
;
Hao GUO
2
;
Yujie LI
3
;
Yanan ZHANG
3
Author Information
1. Dept.of Pharmacy，Inner Mongolia People’s Hospital，Hohhot 010017，China;School of Pharmacy，Inner Mongolia Medical University，Hohhot 010059，China
2. Dept.of Pharmacy，Inner Mongolia People’s Hospital，Hohhot 010017，China;Inner Mongolia Autonomous Region Essential Drug Monitoring and Clinical Comprehensive Evaluation Center，Hohhot 010017，China
3. Dept.of Pharmacy，Inner Mongolia People’s Hospital，Hohhot 010017，China
- Publication Type:Journal Article
- Keywords:
ezetimibe;
hybutimibe;
cholesterol absorption inhibitor;
dyslipidemia;
statins;
network meta-analysis
- From:
China Pharmacy
2026;37(14):1912-1917
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the efficacy and safety of cholesterol absorption inhibitors （ezetimibe and hybutimibe） combined with statins for the treatment of dyslipidemia. METHODS Randomized controlled trials （RCTs） about above-mentioned drug combination in patients with dyslipidemia were retrieved from CNKI，PubMed and other Chinese and English databases. The retrieval time limit was from the establishment of the database to October 2025. After screening the literature，extracting the data，and evaluating the quality of the literature，network meta-analysis was performed using R software. RESULTS A total of 36 RCTs were included. Results showed that in reducing low-density lipoprotein cholesterol （LDL-C） and total cholesterol （TC）， ezetimibe+statins and hybutimibe+statins were significantly superior to statins+placebo and placebo alone （ P ＜0.05）. The top two interventions according to surface under the cumulative ranking curve （SUCRA） rankings were both ezetimibe+statins and hybutimibe+statins. In terms of triglyceride （TG） lowering， both hybutimibe+statins and ezetimibe+statins were significantly better than statins alone， statins+placebo and placebo alone （ P ＜0.05）， with hybutimibe+statins and ezetimibe+statins ranking top two by SUCRA. For apolipoprotein B （ApoB） reduction， ezetimibe+statins was significantly superior to statins alone and placebo alone （ P ＜0.05）， and the top two SUCRA rankings were ezetim ibe+statins and statins+placebo. In terms of high-density lipoprotein cholesterol （HDL-C） increase， placebo was significantly better than statins alone， hybutimibe+statins， statins+placebo， and ezetimibe+statins （ P ＜0.05）， and the top two SUCRA rankings were placebo alone and statins alone.There was no statistically significant difference in the overall incidence of adverse reactions among the interventions （ P ＞0.05）. CONCLUSIONS Ezetimibe combined with statins shows significant advantages in reducing LDL-C， TC and ApoB， while the hybutimibe combined with statins may have potential advantages in lowering TG； both combination regimens have good safety.
